

6. REFERENCES

1. What is Neurodegenerative Disease? *JPND Research*, Retrieved April 2, **2016**.
2. Alzheimer's disease fact sheet. *National Institute on Ageing*, May **2015**: p. Retrieved April 10 2016.
3. Klafki, HW, Staufenbiel M, Kornhuber J and Wiltfang J. Therapeutic approaches to Alzheimer's disease. *Brain*, **2006**. 129 (11): p. 2840-2855.
4. Melnikova I. Therapies for Alzheimer's disease. *Nat Rev Drug Discov*, **2007**. 6 (5): p. 341-342.
5. Nelson PT, Braak H and Markesbery WR. Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship. *J Neuropathol Exp Neurol*, **2009**. 68 (1): p. 1-14.
6. Ryan NS and Rossor MN. Correlating familial Alzheimer's disease gene mutations with clinical phenotype. *Biomark Med*, **2010**. 4 (1): p. 99-112.
7. Liu, CC, Kanekiyo T, Xu H and Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy. *Nature reviews. Neurology*, **2013**. 9 (2): p. 106-118.
8. Maccioni RB, Farias G, Morales I and Navarrete L. The revitalized tau hypothesis on Alzheimer's disease. *Arch Med Res*, **2010**. 41 (3): p. 226-231.
9. Rottkamp CA, Raina AK, Zhu X, Gaier E, Bush AI, Atwood CS, *et al*. Redox-active iron mediates amyloid-beta toxicity. *Free Radic Biol Med*, **2001**. 30 (4): p. 447-450.
10. Behl C. Apoptosis and Alzheimer's disease. *J Neural Transm*, **2000**. 107 (11): p. 1325-1344.
11. Shimohama S. Apoptosis in Alzheimer's disease--an update. *Apoptosis*, **2000**. 5 (1): p. 9-16.
12. Hitti FL and Siegelbaum SA. The hippocampal CA2 region is essential for social memory. *Nature*, **2014**. 508 (7494): p. 88-92.
13. Myhre O, Utkilen H, Duale N, Brunborg G and Hofer T. Metal Dyshomeostasis and Inflammation in Alzheimer's and Parkinson's Diseases: Possible Impact of Environmental Exposures. *Oxi Med Cell Longev*, **2013**. 2013: p. 19.
14. Tucci P, Mhillaj E, Morgese MG, Colaianna M, Zotti M, Schiavone S, *et al*. Memantine prevents memory consolidation failure induced by soluble beta amyloid in rats. *Front Behav Neurosci*, **2014**. 8: p. 332.
15. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, *et al*. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. *Nature*, **1999**. 400 (6740): p. 173-177.
16. Yan SS, Chen D, Yan S, Guo L, Du H and Chen JX. RAGE is a key cellular target for A β -induced perturbation in Alzheimer's disease. *Front Biosci*, **2012**. 4: p. 240-250.
17. Ghosh AK, Brindisi M and J Tang. Developing β secretase inhibitors for treatment of Alzheimer's disease. *J Neurochem*, **2012**. 120 (s1): p. 71-83.
18. Chang WP, Huang X, Downs D, Cirrito JR, Koelsch G, Holtzman DM, *et al*. β -Secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. *FASEB J*, **2011**. 25 (2): p. 775-784.

19. Janusz M and Zablocka A. Colostral Proline-Rich Polypeptides-Immunoregulatory Properties and Prospects of Therapeutic Use in Alzheimer's Disease. *Curr Alzheimers Res*, **2010**. 7 (4): p. 323-333.
20. Saito T, Iwata N, Tsubuki S, Takaki Y, Takano J, Huang SM, *et al*. Somatostatin regulates brain amyloid β peptide A β 42 through modulation of proteolytic degradation. *Nat Med*, **2005**. 11 (4): p. 434-439.
21. Hock C and Nitsch RM. Clinical observations with AN-1792 using TAPIR analyses. *Neurodegen Dis*, **2006**. 2 (5): p. 273-276.
22. Lovestone S, Boada M, Dubois B, Hull M, Rinne JO, Huppertz HJ, *et al*. A phase II trial of tideglusib in Alzheimer's disease. *J Alzheimers Dis*, **2015**. 45 (1): p. 75-88.
23. Gozes I. NAP (davunetide) provides functional and structural neuroprotection. *Curr Pharma Des*, **2011**. 17 (10): p. 1040-1044.
24. Pfaffendorf M, Bruning T, Batink H and Van Zwieten P. The interaction between methylene blue and the cholinergic system. *Br J Pharmacol*, **1997**. 122 (1): p. 95-98.
25. Ma QL, Zuo X, Yang F, Ubeda OJ, Gant DJ, Alaverdyan M, *et al*. Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice. *J Biol Chem*, **2013**. 288 (6): p. 4056-4065.
26. Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, *et al*. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. *J Biol Chem*, **2011**. 286 (39): p. 34457-34467.
27. Maher-Edwards G, De'Ath J, Barnett C, Lavrov A and Lockhart A. A 24-week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease. *Alzheimers Dement*, **2015**. 1 (2): p. 131-140.
28. Echeverria V and R Zeitlin. Cotinine: a potential new therapeutic agent against Alzheimer's disease. *CNS Neurosci Ther*, **2012**. 18 (7): p. 517-523.
29. Marcade M, Bourdin J, Loiseau N, Peillon H, Rayer A, Drouin D, *et al*. Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. *J Neurochem*, **2008**. 106 (1): p. 392-404.
30. Atri A, Molinuevo JL, Lemming O, Wirth Y, Pulte I and Wilkinson D. Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy. *Alzheimers Res Ther*, **2013**. 5 (1): p. 6.
31. Patat A, Parks V, Raje S, Plotka A, Chassard D and Le Coz F. Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects. *Br J Clin Pharmacol*, **2009**. 67 (3): p. 299-308.
32. Gravius A, Laszy J, Pietraszek M, Saghy K, Nagel J, Chambon C, *et al*. Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity. *Behav Pharmacol*, **2011**. 22 (2): p. 122-135.

33. Haig GM, Pritchett Y, Meier A, Othman AA, Hall C, Gault LM, *et al.* A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia. *J Alzheimers Dis*, **2014**. 42 (3): p. 959-971.
34. J Nathan P, Boardley R, Scott N, Berges A, Maruff P, Sivananthan T, *et al.* The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H3 receptor antagonist in patients with mild to moderate Alzheimer's disease: a preliminary investigation. *Curr Alzheimer Res*, **2013**. 10 (3): p. 240-251.
35. Calkins, MJ, Manczak M and Reddy PH. Mitochondria-Targeted Antioxidant SS31 Prevents Amyloid Beta-Induced Mitochondrial Abnormalities and Synaptic Degeneration in Alzheimer's Disease. *Pharmaceuticals*, **2012**. 5 (10): p. 1103-1119.
36. Cardinali DP, Furio AM and Brusco LI. Clinical aspects of melatonin intervention in Alzheimer's disease progression. *Curr Neuropharmacol*, **2010**. 8 (3): p. 218-227.
37. Choi SH, Aid S, Caracciolo L, Minami SS, Niikura T, Matsuoka Y, *et al.* Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease. *J Neurochem*, **2013**. 124 (1): p. 59-68.
38. Yang WC, Sun Q, Yu NX, Zhu XL and Yang GF. Design of acetylcholinesterase inhibitor for Alzheimer's disease therapy: from multi-binding site inhibitors to multi-target directed ligands. *Yao Xue Xue Bao*, **2012**. 47 (3): p. 313-321.
39. Yogev-Falach M, Bar-Am O, Amit T, Weinreb O and Youdim MB. A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. *FASEB J*, **2006**. 20 (12): p. 2177-2179.
40. J. Richard Morphy CJH. Designing Multi-Target Drugs. *RSC Drug Discovery*, **2012**.
41. Inestrosa NC and Varela-Nallar L. Wnt signaling in the nervous system and in Alzheimer's disease. *J Mol Cell Biol*, **2014**. 6 (1): p. 64-74.
42. Zhu X, Wang S, Yu L, Yang H, Tan R, Yin K, *et al.* TL-2 attenuates β -amyloid induced neuronal apoptosis through the AKT/GSK-3 β / β -catenin pathway. *Int J Neuropsychopharmacol*, **2014**. 17 (9): 1511-1519.
43. Gao Z, Ure K, Ables JL, Lagace DC, Nave KA, Goebbels S, *et al.* Neurod1 is essential for the survival and maturation of adult-born neurons. *Nat Neurosci*, **2009**. 12 (9): p. 1090.
44. Kuwabara T, Hsieh J, Muotri A, Yeo G, Warashina M, Lie DC, *et al.* Wnt-mediated activation of NeuroD1 and retro-elements during adult neurogenesis. *Nat Neurosci*, **2009**. 12 (9): p. 1097-1105.
45. De Ferrari, GV, Chacon MA, Barria MI, Garrido JL, Godoy JA, Olivares G, *et al.* Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. *Mol Psychiatry*, **2003**. 8 (2): p. 195-208.
46. Graham D. W., R., E. F. U.S. Patent 4,173,631. 1979.
47. Barthel A, Trieschmann L, Strohl D, Kluge R, Bohm G and Csuk R. Synthesis of dimeric quinazolin-2-one, 1,4-benzodiazepin-2-one, and isoalloxazine compounds as inhibitors of amyloid peptides association. *Arch Pharm*, **2009**. 342 (8): p. 445-452.

48. Ellman GL, Courtney KD, Andres V and Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem Pharmacol*, **1961**. 7: p. 88-95.
49. Kwon YE, Park JY, No KT, Shin JH, Lee SK, Eun JS, *et al.* Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics. *Bioorg Med Chem*, **2007**. 15 (20): p. 6596-607.
50. Mohamed T, Zhao X, Habib LK, Yang J and Rao PP. Design, synthesis and structure-activity relationship (SAR) studies of 2,4-disubstituted pyrimidine derivatives: dual activity as cholinesterase and Abeta-aggregation inhibitors. *Bioorg Med Chem*, **2011**. 19 (7): p. 2269-2281.
51. Klunk WE, Jacob RF and Mason RP. Quantifying amyloid beta-peptide (Abeta) aggregation using the Congo red-Abeta (CR-abeta) spectrophotometric assay. *Anal Biochem*, **1999**. 266 (1): p. 66-76.
52. Kang IJ, Jeon YE, Yin XF, Nam JS, You SG, Hong MS, *et al.* Butanol extract of *Ecklonia cava* prevents production and aggregation of beta-amyloid, and reduces beta-amyloid mediated neuronal death. *Food Chem Toxicol*, **2011**. 49 (9): p. 2252-2259.
53. Porcal W, Hernandez P, Gonzalez M, Ferreira A, Olea-Azar C, Cerecetto H, *et al.* Heteroarylnitrones as drugs for neurodegenerative diseases: synthesis, neuroprotective properties, and free radical scavenger properties. *J Med Chem*, **2008**. 51 (19): p. 6150-6159.
54. Blat D, Weiner L, Youdim MB and Fridkin M. A Novel iron-chelating derivative of the neuroprotective peptide NAPVSIPQ shows superior antioxidant and antineurodegenerative capabilities. *J Med Chem*, **2008**. 51 (1): p. 126-134.
55. Chen Y, Sun J, Fang L, Liu M, Peng S, Liao H, *et al.* Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors. *J Med Chem*, **2012**. 55 (9): p. 4309-4321.
56. Kedare, SB and Singh RP. Genesis and development of DPPH method of antioxidant assay. *J Food Sci Technol*, **2011**. 48 (4): p. 412-422.
57. Mathew M and Subramanian S. In vitro screening for anti-cholinesterase and antioxidant activity of methanolic extracts of ayurvedic medicinal plants used for cognitive disorders. *PloS one*, **2014**. 9 (1).
58. Di L, Kerns EH, Fan K, McConnell OJ and Carter GT. High throughput artificial membrane permeability assay for blood-brain barrier. *Eur J Med Chem*, **2003**. 38 (3): p. 223-232.
59. Cetin F, Yazihan N, Dincer S and Akbulut G. The effect of intracerebroventricular injection of beta amyloid peptide (1-42) on caspase-3 activity, lipid peroxidation, nitric oxide and NOS expression in young adult and aged rat brain. *Turk Neurosurg*, **2013**. 23 (2): p. 144-150.
60. Lu C, Guo Y, Yan J, Luo Z, Luo HB, Yan M, *et al.* Design, synthesis, and evaluation of multitarget-directed resveratrol derivatives for the treatment of Alzheimer's disease. *J Med Chem*, **2013**. 56 (14): p. 5843-5859.

61. Kwon SH, Lee HK, Kim JA, Hong SI, Kim HC, Jo TH, *et al.* Neuroprotective effects of chlorogenic acid on scopolamine-induced amnesia via anti-acetylcholinesterase and anti-oxidative activities in mice. *Eu J Pharmacol*, **2010**. 649 (1-3): p. 210-217.
62. D'Hooge R and De Deyn PP. Applications of the Morris water maze in the study of learning and memory. *Brain Res Brain Res Rev*, **2001**. 36 (1): p. 60-90.
63. Goverdhan P, Sravanthi A and Mamatha T. Neuroprotective effects of meloxicam and selegiline in scopolamine-induced cognitive impairment and oxidative stress. *Int J Alzheimers Dis*, **2012**. 2012: p. 974013.
64. Ohkawa H, Ohishi N and Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. *Anal Biochem*, **1979**. 95 (2): p. 351-358.
65. Sinha AK. Colorimetric assay of catalase. *Anal Biochem*, **1972**. 47 (2): p. 389-394.
66. Kaech S and Banker G. Culturing hippocampal neurons. *Nat Protoc*, **2006**. 1 (5): p. 2406-2415.
67. Zha YY, Yang B, Tang ML, Guo QC, Chen JT, Wen LP, *et al.* Concentration-dependent effects of fullerene on cultured hippocampal neuron viability. *Int J Nanomedicine*, **2012**. 7: p. 3099-3109.
68. Liu D, Zhang H, Gu W, Liu Y and Zhang M. Neuroprotective effects of ginsenoside Rb1 on high glucose-induced neurotoxicity in primary cultured rat hippocampal neurons. *PLoS One*, **2013**. 8 (11): p. e79399.
69. Yao M, Nguyen TV and Pike CJ. Beta-amyloid-induced neuronal apoptosis involves c-Jun N-terminal kinase-dependent downregulation of Bcl-w. *J Neurosci*, **2005**. 25 (5): p. 1149-1158.
70. Muirhead KE, Borger E, Aitken L, Conway SJ and Gunn-Moore FJ. The consequences of mitochondrial amyloid beta-peptide in Alzheimer's disease. *Biochem J*, **2010**. 426 (3): p. 255-270.
71. Zhou S, Yang Y, Gu X and Ding F. Chitooligosaccharides protect cultured hippocampal neurons against glutamate-induced neurotoxicity. *Neurosci Lett*, **2008**. 444 (3): p. 270-274.
72. Jeruc J, Vizjak A, Rozman B and Ferluga D. Immunohistochemical expression of activated caspase-3 as a marker of apoptosis in glomeruli of human lupus nephritis. *Am J Kidney Dis*, **2006**. 48 (3): p. 410-418.
73. Brecht S, Gelderblom M, Srinivasan A, Mielke K, Dityateva G and Herdegen T. Caspase-3 activation and DNA fragmentation in primary hippocampal neurons following glutamate excitotoxicity. *Brain Res Mol Brain Res*, **2001**. 94 (1-2): p. 25-34.
74. Troy CM, Friedman JE and Friedman WJ. Mechanisms of p75-mediated death of hippocampal neurons. Role of caspases. *J Biol Chem*, **2002**. 277 (37): p. 34295-34302.
75. Colaianna M, Tucci P, Zotti M, Morgese MG, Schiavone S, Govoni S, *et al.* Soluble beta amyloid(1-42): a critical player in producing behavioural and biochemical changes evoking depressive-related state? *Br J Pharmacol*, **2010**. 159 (8): p. 1704-1715.

76. Yan JJ, Cho JY, Kim HS, Kim KL, Jung JS, Huh SO, *et al.* Protection against beta-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. *Br J Pharmacol*, **2001**. 133 (1): p. 89-96.
77. Luo Z, Sheng J, Sun Y, Lu C, Yan J, Liu A, *et al.* Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen. *J Med Chem*, **2013**. 56 (22): p. 9089-9099.
78. Eskander MF, Nagykerly NG, Leung EY, Khelghati B and Geula C. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles. *Brain Res*, **2005**. 1060 (1-2): p. 144-152.
79. Giacobini E. Cholinesterases and cholinesterase inhibitors. **2000**: Martin Dunitz; Distributed in the United States by Blackwell Science.
80. Mesulam M, Guillozet A, Shaw P and Quinn B. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. *Neurobiol Dis*, **2002**. 9 (1): p. 88-93.
81. Alvarez A, Guillozet A, Shaw P and Quinn B. Acetylcholinesterase, a senile plaque component, affects the fibrillogenesis of amyloid-beta-peptides. *Neurosci Lett*, **1995**. 201 (1): p. 49-52.
82. Alvarez A, Opazo C, Alarcon R, Garrido J and Inestrosa NC. Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. *J Mol Biol*, **1997**. 272 (3): p. 348-361.
83. Crivori P, Cruciani G, Carrupt PA and Testa B. Predicting blood-brain barrier permeation from three-dimensional molecular structure. *J Med Chem*, **2000**. 43 (11): p. 2204-2216.
84. Roth KA. Caspases, apoptosis, and Alzheimer disease: causation, correlation, and confusion. *J Neuropathol Exp Neurol*, **2001**. 60 (9): p. 829-838.
85. Hengartner MO. The biochemistry of apoptosis. *Nature*, **2000**. 407 (6805): p. 770-776.
86. Butterfield DA. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. *Free Radic Res*, **2002**. 36 (12): p. 1307-1313.
87. Sinha A, Tamboli RS, Seth B, Kanhed AM, Tiwari SK, Agarwal S, *et al.* Neuroprotective Role of Novel Triazine Derivatives by Activating Wnt/beta Catenin Signaling Pathway in Rodent Models of Alzheimer's Disease. *Mol Neurobiol*, **2015**. 52 (1): p. 638-652.
88. Aguzzi A and O'Connor T. Protein aggregation diseases: pathogenicity and therapeutic perspectives. *Nat Rev Drug Discov*, **2010**. 9 (3): p. 237-248.
89. Boonen RA, Tijn PV and Zivkovic D. Wnt signaling in Alzheimer's disease: up or down, that is the question. *Ageing Res Rev*, **2009**. 8 (2): p. 71-82.
90. Zhu X, Wang S, Yu L, Yang H, Tan R, Yin K, *et al.* TL-2 attenuates beta-amyloid induced neuronal apoptosis through the AKT/GSK-3beta/beta-catenin pathway. *Int J Neuropsychopharmacol*, **2014**. 17 (9): p. 1511-1519.

91. Fuentealba RA, Farias G, Scheu J, Bronfman M, Marzolo MP and Inestrosa NC. Signal transduction during amyloid-beta-peptide neurotoxicity: role in Alzheimer disease. *Brain Res Brain Res Rev*, **2004**. 47 (1-3): p. 275-289.
92. Shruster A, Eldar Finkelman H, Melamed E and Offen D. Wnt signaling pathway overcomes the disruption of neuronal differentiation of neural progenitor cells induced by oligomeric amyloid β peptide. *J Neurochem*, **2011**. 116 (4): p. 522-529.
93. Tiwari SK, Agarwal S, Seth B, Yadav A, Nair S, Bhatnagar P, *et al*. Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in alzheimer's disease model via canonical Wnt/ β -catenin pathway. *ACS Nano*, **2013**. 8 (1): p. 76-103.
94. Darvesh S, Hopkins DA and Geula C. Neurobiology of butyrylcholinesterase. *Nat Rev Neurosci*, **2003**. 4 (2): p. 131-138.
95. Murphy MP and LeVine H. Alzheimer's disease and the amyloid-beta peptide. *J Alzheimers Dis*, **2010**. 19 (1): p. 311-323.
96. Pakaski M and Kalman J. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease. *Neurochem Int*, **2008**. 53 (5): p. 103-111.
97. Carvajal FJ and Inestrosa NC. Interactions of AChE with A β Aggregates in Alzheimer's Brain: Therapeutic Relevance of IDN 5706. *Front Mol Neurosci*, **2011**. 4: p. 19.
98. Inestrosa NC, Dinamarca MC and Alvarez A. Amyloid-cholinesterase interactions. Implications for Alzheimer's disease. *FEBS J*, **2008**. 275 (4): p. 625-632.
99. Elmlinger MW, Kriebel M and Ziegler D. Neuroprotective and anti-oxidative effects of the hemodialysate actovegin on primary rat neurons in vitro. *Neuromolecular Med*, **2011**. 13 (4): p. 266-274.
100. Blurton-Jones M and Laferla FM. Pathways by which A β facilitates tau pathology. *Curr Alzheimer Res*, **2006**. 3 (5): p. 437-448.
101. Dobarro M, Gerenu G and Ramirez MJ. Propranolol reduces cognitive deficits, amyloid and tau pathology in Alzheimer's transgenic mice. *Int J Neuropsychopharmacol*, **2013**. 16 (10): p. 2245-2257.
102. Lee DH, Park T and Kim HW. Induction of apoptosis by disturbing mitochondrial-membrane potential and cleaving PARP in Jurkat T cells through treatment with acetoxycirpenol mycotoxins. *Biol Pharm Bull*, **2006**. 29 (4): p. 648-654.
103. Oliver FJ, Rubia G, Rolli V, Ruiz-Ruiz MC, Murcia G and Murcia JM. Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. *J Biol Chem*, **1998**. 273 (50): p. 33533-33539.
104. Berger NA. Poly(ADP-ribose) in the cellular response to DNA damage. *Radiat Res*, **1985**. 101 (1): p. 4-15.
105. Chaitanya GV, Steven AJ and Babu PP. PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. *Cell Commun Signal*, **2010**. 8 (1): p. 31.

106. Strosznajder JB, Jesko H and Strosznajder RP. Effect of amyloid beta peptide on poly(ADP-ribose) polymerase activity in adult and aged rat hippocampus. *Acta Biochim Pol*, **2000**. 47 (3): p. 847-854.
107. Adamczyk A, Jesko H and Strosznajder RP. Alzheimer's disease related peptides affected cholinergic receptor mediated poly(ADP-ribose) polymerase activity in the hippocampus. *Folia Neuropathol*, **2005**. 43 (3): p. 139-142.
108. Sairanen T, Szepesi R, Karjalainen-Lindsberg ML, Saksi J, Paetau A and Lindsberg PJ. Neuronal caspase-3 and PARP-1 correlate differentially with apoptosis and necrosis in ischemic human stroke. *Acta Neuropathol*, **2009**. 118 (4): p. 541-552.
109. McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Abrams SL, Montalto G, *et al*. Multifaceted roles of GSK-3 and Wnt/beta-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. *Leukemia*, **2014**. 28 (1): p. 15-33.
110. Stamos JL and Weis WI. The beta-catenin destruction complex. *Cold Spring Harb Perspect Biol*, **2013**. 5 (1): p. a007898.
111. He P and Shen Y. Interruption of β -catenin signaling reduces neurogenesis in Alzheimer's disease. *J Neurosci*, **2009**. 29 (20): p. 6545-6557.
112. Toledo EM and Inestrosa NC. Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APP^{swe}/PSEN1^{DeltaE9} mouse model of Alzheimer's disease. *Mol Psychiatry*, **2010**. 15 (3): p. 272-285.
113. Wang CY, Zheng W, Wang T, Xie JW, Wang SL, Zhao BL, *et al*. Huperzine A activates Wnt/beta-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model. *Neuropsychopharmacol*, **2011**. 36 (5): p. 1073-1089.
114. Dinamarca MC, Sagal JP, Quintanilla RA, Godoy JA, Arrazola MS and Inestrosa NC. Amyloid-beta-Acetylcholinesterase complexes potentiate neurodegenerative changes induced by the A β peptide. Implications for the pathogenesis of Alzheimer's disease. *Mol Neurodegener*, **2010**. 5: p. 4.
115. Farias GG, Godoy JA, Vazquez MC, Adani R, Meshulam H, Avila J, *et al*. The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from beta-amyloid neurotoxicity by acting on Wnt signaling components. *Neurobiol Dis*, **2005**. 18 (1): p. 176-183.

6. REFERENCES

1. Vialli M and Erspamer DV. Ricerche sul secreto delle cellule enterocromaffini. *Z Zellforsch Mikrosk Anat Histochem*, **1937**. 27 (1): p. 81-99.
2. Colowick SP. Arda Alden Green, Protein Chemist. *Science*, **1958**. 128 (3323): p. 519-521.
3. Rapport MM, Green AA and Page IH. Partial purification of the vasoconstrictor in beef serum. *J Biol Chem*, **1948**. 174 (2): p. 735-741.
4. Hamlin K and Fischer F. The synthesis of 5-hydroxytryptamine. *J Ame Chem Soc*, **1951**. 73 (10): p. 5007-5008.
5. Erspamer V and Asero B. Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine. *Nature*, **1952**. 169 (4306): p. 800-801.
6. Twarog BM and Page IH. Serotonin content of some mammalian tissues and urine and a method for its determination. *Am J Physiol*, **1953**. 175 (1): p. 157-161.
7. Hofmann A. LSD: My Problem Child; Tarcher: Los Angeles, CA. **1979**.
8. Woolley DW and Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. *Proc Natl Acad Sci*, **1954**. 40 (4): p. 228-231.
9. Hoyer D, Hannon JP and Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. *Pharmacol Biochem Behav*, **2002**. 71 (4): p. 533-554.
10. Nichols DE and Nichols CD. Serotonin receptors. *Chem Rev*, **2008**. 108 (5): p. 1614-1641.
11. Cutrer, FM, Yu X-J, Ayata G, Moskowitz MA and Waeber C. Effects of PNU-109,291, a selective 5-HT 1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis. *Neuropharmacol*, **1999**. 38 (7): p. 1043-1053.
12. Klein MT and Teitler M. Guinea pig hippocampal 5 HT1E receptors: a tool for selective drug development. *J Neurochem*, **2009**. 109 (1): p. 268-274.
13. Gaddum JH and Picarelli ZP. Two kinds of tryptamine receptor. *Br J Pharmacol Chemother*, **1957**. 12 (3): p. 323-328.
14. Martin P, Waters N, Schmidt CJ, Carlsson A and Carlsson ML. Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone. *J Neural Transm*, **1998**. 105 (4-5): p. 365-396.
15. Kovacs A, Gacsalyi I, Wellmann J, Schmidt E, Szucs Z, Dubreuil V *et al*. Effects of EGIS-7625, a selective and competitive 5-HT_{2B} receptor antagonist. *Cardiovasc Drugs Ther*, **2003**. 17 (5-6): p. 427-434.
16. Fletcher PJ, Tampakeras M, Sinyard J, Slassi A, Isaac M and Higgins GA. Characterizing the effects of 5-HT 2C receptor ligands on motor activity and feeding behaviour in 5-HT 2C receptor knockout mice. *Neuropharmacol*, **2009**. 57 (3): p. 259-267.
17. Fletcher PJ, Rizos Z, Noble K, Soko AD, Sileniaks LB, Le AD and Higgins GA. Effects of the 5-HT_{2C} receptor agonist Ro60-0175 and the 5-HT_{2A} receptor antagonist M100907 on nicotine self-administration and reinstatement. *Neuropharmacol*, **2012**. 62 (7): p. 2288-2298.

18. Nilsson BM. 5-Hydroxytryptamine 2C (5-HT_{2C}) receptor agonists as potential antiobesity agents. *J Med Chem*, **2006**. 49 (14): p. 4023-4034.
19. Thompson AJ and Lummis SCR. 5-HT(3) Receptors. *Curr Pharma Des*, **2006**. 12 (28): p. 3615-3630.
20. Lezoualc'h F and Robert SJ. The serotonin 5-HT₄ receptor and the amyloid precursor protein processing. *Exp Gerontol*, **2003**. 38 (1-2): p. 159-166.
21. Barnes NM and Neumaier JF. Neuronal 5-HT receptors and SERT. *Tocris Biosci Scient Rev Ser*, **2011**. 34: p. 1-15.
22. Thomas DR. 5-HT_{5A} receptors as a therapeutic target. *Pharmacol Therap*, **2006**. 111 (3): p. 707-714.
23. Karila D, Freret T, Bouet V, Boulouard M, Dallemagne P and Rochais C. Therapeutic Potential of 5-HT₆ Receptor Agonists. *J Med Chem*, **2015**. 58 (20): p. 7901-712.
24. Marazziti D, Baroni S, Borsini F, Picchetti M, Vatteroni E, Falaschi V *et al*. Serotonin receptors of type 6 (5-HT₆): from neuroscience to clinical pharmacology. *Curr Med Chem*, **2013**. 20 (3): p. 371-377.
25. Mnie-Filali O, Faure C, Lambas-Senas L, El Mansari M, Belblidia H, Gondard E *et al*. Pharmacological blockade of 5-HT₇ receptors as a putative fast acting antidepressant strategy. *Neuropsychopharmacol*, **2011**. 36 (6): p. 1275-1288.
26. Heisler LK, Zhou L, Bajwa P, Hsu J and Tecott LH. Serotonin 5-HT_{2C} receptors regulate anxiety-like behavior. *Genes Brain Behav*, **2007**. 6 (5): p. 491-496.
27. Bai B and Wang Y. The use of lorcaserin in the management of obesity: a critical appraisal. *Drug Des Devel Ther*, **2010**. 5: p. 1-7.
28. Halford JC and Harrold JA. 5-HT_{2C} receptor agonists and the control of appetite, in *Appetite Control*. **2012**, Springer. p. 349-356.
29. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ *et al*. Evidence for possible involvement of 5-HT_{2B} receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. *Circulation*, **2000**. 102 (23): p. 2836-2841.
30. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S *et al*. Multicenter, placebo-controlled trial of lorcaserin for weight management. *New Eng J Med*, **2010**. 363 (3): p. 245-256.
31. Millan MJ. Serotonin 5-HT_{2C} receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. *Therapie*, **2005**. 60 (5): p. 441-460.
32. Millan MJ, Brocco M, Gobert A and Dekeyne A. Anxiolytic properties of agomelatine, an antidepressant with melatonergic and serotonergic properties: role of 5-HT_{2C} receptor blockade. *Psychopharmacol*, **2005**. 177 (4): p. 448-458.
33. Campbell BM and Merchant KM. Serotonin 2C receptors within the basolateral amygdala induce acute fear-like responses in an open-field environment. *Brain Res*, **2003**. 993 (1-2): p. 1-9.
34. LeDoux J. The emotional brain, fear, and the amygdala. *Cell Mol Neurobiol*, **2003**. 23 (4-5): p. 727-738.

35. Bagdy G, Graf M, Anheuer ZE, Modos EA and Kantor S. Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT_{2C} receptor antagonist SB-242084 but not the 5-HT_{1A} receptor antagonist WAY-100635. *Int J Neuropsychopharmacol*, **2001**. 4 (4): p. 399-408.
36. Cornelio AM and Nunes-de-Souza RL. Anxiogenic-like effects of mCPP microinfusions into the amygdala (but not dorsal or ventral hippocampus) in mice exposed to elevated plus-maze. *Behav Brain Res*, **2007**. 178 (1): p. 82-89.
37. Boothman L, Allers K, Rasmussen K and Sharp T. Evidence that central 5-HT_{2A} and 5-HT_{2B/C} receptors regulate 5-HT cell firing in the dorsal raphe nucleus of the anaesthetised rat. *Bri J Pharmacol*, **2003**. 139 (5): p. 998-1004.
38. Dremencov E, El Mansari M and Blier P. Effects of sustained serotonin reuptake inhibition on the firing of dopamine neurons in the rat ventral tegmental area. *J Psychiatry Neurosci*, **2009**. 34 (3): p. 223-229.
39. Rajkumar R, Pandey DK, Mahesh R and Radha R. 1-(m-Chlorophenyl)piperazine induces depressogenic-like behaviour in rodents by stimulating the neuronal 5-HT_{2A} receptors: proposal of a modified rodent antidepressant assay. *Eur J Pharmacol*, **2009**. 608 (1-3): p. 32-41.
40. Bockaert J, Claeysen S, Becamel C, Dumuis A and Marin P. Neuronal 5-HT metabotropic receptors: fine-tuning of their structure, signaling, and roles in synaptic modulation. *Cell Tissue Res*, **2006**. 326 (2): p. 553-572.
41. Di Giovanni G, Di Matteo V, La Grutta V and Esposito E. m-Chlorophenylpiperazine excites non-dopaminergic neurons in the rat substantia nigra and ventral tegmental area by activating serotonin-2C receptors. *Neuroscience*, **2001**. 103 (1): p. 111-116.
42. Andersson KE. Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. *Pharmacol Rev*, **2011**. 63 (4): p. 811-859.
43. Kimura Y, Naitou Y, Wanibuchi F and Yamaguchi T. 5-HT_{2C} receptor activation is a common mechanism on proerectile effects of apomorphine, oxytocin and melanotan-II in rats. *Eur J Pharmacol*, **2008**. 589 (1-3): p. 157-162.
44. Villalón CM and Centurion D. Cardiovascular responses produced by 5-hydroxytryptamine: a pharmacological update on the receptors/mechanisms involved and therapeutic implications. *Naunyn Schmiedeberg's Arch Pharmacol*, **2007**. 376 (1-2): p. 45-63.
45. Roth BL. Drugs and valvular heart disease. *N Engl J Med*, **2007**. 356 (1): p. 6-9.
46. McKune CM and Watts SW. Characterization of the serotonin receptor mediating contraction in the mouse thoracic aorta and signal pathway coupling. *J Pharmacol Exp Ther*, **2001**. 297 (1): p. 88-95.
47. Yadav MR, Gandhi HP, Naik PP and Giridhar R. Revelation on the potency of alpha(1) - blockers - parallel blockade of angiotensin II receptor: a new finding. *Pharm Biol*, **2012**. 50 (4): p. 439-442.
48. NK KSSVJ. Modified method of preparing longitudinal and horizontal rat fundal strips for bioassay. *Ind J Pharmacol*, **2001**. 33 (3): p. 219-220.

49. Porsolt RD, Brossard G, Hautbois C and Roux S. Rodent models of depression: forced swimming and tail suspension behavioral despair tests in rats and mice. *Curr Protoc Neurosci*, **2001**. Chapter 8: p. Unit 8 10A.
50. Komada M, Takao K and Miyakawa T. Elevated plus maze for mice. *J Vis Exp*, **2008**. 22.
51. Bonhaus DW, Weinhardt KK, Taylor M, DeSouza A, McNeeley PM, Szczepanski K *et al*. RS-102221: a novel high affinity and selective, 5-HT_{2C} receptor antagonist. *Neuropharmacol*, **1997**. 36 (4-5): p. 621-629.
52. Kuznetsova EG, Amstislavskaya TG, Shefer EA and Popova NK. Effect of 5-HT_{2C} receptor antagonist RS 102221 on mouse behavior. *Bull Exp Biol Med*, **2006**. 142 (1): p. 76-79.
53. Schreiber R and De Vry J. Role of 5-HT_{2C} receptors in the hypophagic effect of m-CPP, ORG 37684 and CP-94,253 in the rat. *Prog Neuropsychopharmacol Biol Psychiatry*, **2002**. 26 (3): p. 441-449.
54. Chagraoui A, Protais P, Filloux T and Mocaer E. Agomelatine(S 20098) antagonizes the penile erections induced by the stimulation of 5-HT_{2C} receptors in Wistar rats. *Psychopharmacol*, **2003**. 170 (1): p. 17-22.
55. Pozzi L, Acconcia S, Ceglia I, Invernizzi RW and Samanin R. Stimulation of 5-hydroxytryptamine (5-HT_{2C}) receptors in the ventro tegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex. *J Neurochem*, **2002**. 82 (1): p. 93-100.
56. Sotty F, Folgering JH, Brennum LT, Hogg S, Mork A, Hertel P and Cremers TI. Relevance of dorsal raphe nucleus firing in serotonin 5-HT_{2C} receptor blockade-induced augmentation of SSRIs effects. *Neuropharmacol*, **2009**. 57 (1): p. 18-24.
57. Mongeau R, Martin CB, Chevarin C, Maldonado R, Hamon M, Robledo P *et al*. 5-HT_{2C} receptor activation prevents stress-induced enhancement of brain 5-HT turnover and extracellular levels in the mouse brain: modulation by chronic paroxetine treatment. *J Neurochem*, **2010**. 115 (2): p. 438-449.
58. Kim C, Speisky MB and Kharouba SN. Rapid and sensitive method for measuring norepinephrine, dopamine, 5-hydroxytryptamine and their major metabolites in rat brain by high-performance liquid chromatography. Differential effect of probenecid, haloperidol and yohimbine on the concentrations of biogenic amines and metabolites in various regions of rat brain. *J Chromatogr*, **1987**. 386: p. 25-35.
59. Chatterjee M, Verma R, Ganguly S and Palit G. Neurochemical and molecular characterization of ketamine-induced experimental psychosis model in mice. *Neuropharmacol*, **2012**. 63 (6): p. 1161-1171.
60. Berg KA, Harvey JA, Spampinato U and Clarke WP. Physiological and therapeutic relevance of constitutive activity of 5-HT_{2A} and 5-HT_{2C} receptors for the treatment of depression. *Prog Brain Res*, **2008**. 172: p. 287-305.
61. Hackler EA, Turner GH, Gresch PJ, Sengupta S, Deutch AY, Avison MJ *et al*. 5-Hydroxytryptamine_{2C} receptor contribution to m-chlorophenylpiperazine and N-methyl-

- beta-carboline-3-carboxamide-induced anxiety-like behavior and limbic brain activation. *J Pharmacol Exp Ther*, **2007**. 320 (3): p. 1023-1029.
62. Harada K, Aota M, Inoue T, Matsuda R, Mihara T, Yamaji T *et al*. Anxiolytic activity of a novel potent serotonin 5-HT_{2C} receptor antagonist FR260010: a comparison with diazepam and buspirone. *Eur J Pharmacol*, **2006**. 553 (1-3): p. 171-184.
 63. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF *et al*. Eating disorder and epilepsy in mice lacking 5-HT_{2c} serotonin receptors. *Nature*, **1995**. 374 (6522): p. 542-546.
 64. Heisler LK, Jobst EE, Sutton GM, Zhou L, Borok E, Thornton-Jones Z *et al*. Serotonin reciprocally regulates melanocortin neurons to modulate food intake. *Neuron*, **2006**. 51 (2): p. 239-249.
 65. Halford JC, Harrold JA, Boyland EJ, Lawton CL and Blundell JE. Serotonergic drugs : effects on appetite expression and use for the treatment of obesity. *Drugs*, **2007**. 67 (1): p. 27-55.
 66. Garfield AS and Heisler LK. Pharmacological targeting of the serotonergic system for the treatment of obesity. *J Physiol*, **2009**. 587 (1): p. 49-60.
 67. Higgs S, Cooper AJ and Barnes NM. Reversal of sibutramine-induced anorexia with a selective 5-HT_{2C} receptor antagonist. *Psychopharmacol*, **2011**. 214 (4): p. 941-947.
 68. Bagdy G and Makara GB. Paraventricular nucleus controls 5-HT_{2C} receptor-mediated corticosterone and prolactin but not oxytocin and penile erection responses. *Eur J Pharmacol*, **1995**. 275 (3): p. 301-305.
 69. Millan MJ. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. *Pharmacol Ther*, **2006**. 110 (2): p. 135-370.
 70. Dawson L, Nguyen H, Smith D and Schechter L. Effects of chronic fluoxetine treatment in the presence and absence of (\pm) pindolol: a microdialysis study. *Bri J Pharmacol*, **2000**. 130 (4): p. 797-804.
 71. Beyer CE, Boikess S, Luo B and Dawson LA. Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study. *J Psychopharmacol*, **2002**. 16 (4): p. 297-304.
 72. Dunlop J, Sabb AL, Mazandarani H, Zhang J, Kalgaonker S, Shukhina E *et al*. WAY-163909 [(7bR, 10aR)-1, 2, 3, 4, 8, 9, 10, 10a-Octahydro-7bH-cyclopenta-[b][1, 4] diazepino [6, 7, 1hi] indole], a Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Anorectic Activity. *J Pharmacol Exp Ther*, **2005**. 313 (2): p. 862-869.
 73. Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA *et al*. WAY-163909 [(7bR, 10aR)-1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta-[b][1, 4] diazepino [6, 7, 1hi] indole]: a novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. *J Pharmacol Exp Ther*, **2007**. 320 (1): p. 486-496.

74. Dunlop J, Watts SW, Barrett JE, Coupet J, Harrison B, Mazandarani H *et al.* Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist. *J Pharmacol Exp Ther*, **2011**. 337 (3): p. 673-680.
75. Moreau JL, Bos M, Jenck F, Martin JR, Mortas P and Wichmann J. 5HT_{2C} receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats. *Eur Neuropsychopharmacol*, **1996**. 6 (3): p. 169-175.
76. Sotty F, Folgering JH, Brennum LT, Hogg S, Mork A, Hertel P *et al.* Relevance of dorsal raphe nucleus firing in serotonin 5-HT(2C) receptor blockade-induced augmentation of SSRIs effects. *Neuropharmacol*, **2009**. 57 (1): p. 18-24.
77. Boothman LJ, Allers KA, Rasmussen K and Sharp T. Evidence that central 5-HT_{2A} and 5-HT_{2B/C} receptors regulate 5-HT cell firing in the dorsal raphe nucleus of the anaesthetised rat. *Br J Pharmacol*, **2003**. 139 (5): p. 998-1004.
78. Higgs S, Cooper AJ and Barnes NM. Reversal of sibutramine-induced anorexia with a selective 5-HT(2C) receptor antagonist. *Psychopharmacol*, **2011**. 214 (4): p. 941-947.
79. Millan MJ, Peglioni JL, Lavielle G and Perrin-Monneyron S. 5-HT_{2C} receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists. *Eur J Pharmacol*, **1997**. 325 (1): p. 9-12.
80. Kennett GA, Wood MD, Glen A, Grewal S, Forbes I, Gadre A *et al.* In vivo properties of SB 200646A, a 5-HT_{2C/2B} receptor antagonist. *Br J Pharmacol*, **1994**. 111 (3): p. 797-802.
81. Kennett, GA, Wood MD, Bright F, Cilia J, Piper DC, Gager T *et al.* In vitro and in vivo profile of SB 206553, a potent 5-HT_{2C/5-HT2B} receptor antagonist with anxiolytic-like properties. *Br J Pharmacol*, **1996**. 117 (3): p. 427-434.
82. Bancila M, Verge D, Rampin O, Backstrom JR, Sanders-Bush E, McKenna KE *et al.* 5-Hydroxytryptamine_{2C} receptors on spinal neurons controlling penile erection in the rat. *Neuroscience*, **1999**. 92 (4): p. 1523-1537.

6. REFERENCES

1. Dong X, Wang Y and Qin Z. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. *Acta Pharmacol Sin*, **2009**. 30 (4): p. 379-387.
2. Lucas D and Newhouse J. The toxic effect of sodium L-glutamate on the inner layers of the retina. *AMA Arch Ophthalmol*, **1957**. 58 (2): p. 193-201.
3. Olney JW. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. *Science*, **1969**. 164 (3880): p. 719-21.
4. Olney JW and Sharpe LG. Brain lesions in an infant rhesus monkey treated with monosodium glutamate. *Science*, **1969**. 166 (3903): p. 386-388.
5. Rothman S. Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death. *J Neurosci*, **1984**. 4 (7): p. 1884-1891.
6. Lau A and Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. *Pflugers Arch*, **2010**. 460 (2): p. 525-42.
7. Mayer ML. Glutamate receptor ion channels. *Curr Opin Neurobiol*, **2005**. 15 (3): p. 282-8.
8. Johnson JW and Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. *Nature*, **1987**. 325 (6104): p. 529-31.
9. Cull-Candy S, Brickley S and Farrant M. NMDA receptor subunits: diversity, development and disease. *Curr Opin Neurobiol*, **2001**. 11 (3): p. 327-35.
10. Bruno V, Copani A, Knopfel T, Kuhn R, Casabona G, Dell'Albani P *et al*. Activation of class II or III metabotropic glutamate receptors protects cultured cortical neurons against excitotoxic degeneration. *Eur J Neurosci*, **1995**. 7 (9): p. 1906-1913.
11. Emerit J, Edeas M and Bricaire F. Neurodegenerative diseases and oxidative stress. *Biomed Pharmacother*, **2004**. 58 (1): p. 39-46.
12. Zucker RS and Regehr WG. Short-term synaptic plasticity. *Ann Rev Physiol*, **2002**. 64 (1): p. 355-405.
13. Aarts MM and Tymianski M. Molecular mechanisms underlying specificity of excitotoxic signaling in neurons. *Curr Mol Med*, **2004**. 4 (2): p. 137-47.
14. Mattson MP. Apoptosis in neurodegenerative disorders. *Nat Rev Mol Cell Biol*, **2000**. 1 (2): p. 120-9.
15. Waxman EA and Lynch DR. N-methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. *Neuroscientist*, **2005**. 11 (1): p. 37-49.
16. Sun, G.Y., Xu J, Jensen MD, Simonyi A. Phospholipase A2 in the central nervous system implications for neurodegenerative diseases. *J Lipid Res*, **2004**. 45 (2): p. 205-213.
17. Uttara, B., Singh AV, Zamboni P, Mahajan RT. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. *Curr Neuropharmacol*, **2009**. 7 (1): p. 65-74.
18. Butterfield, DA, Reed T, Newman SF, Sultana R. Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. *Free Radic Biol Med*, **2007**. 43 (5): p. 658-77.
19. Carrillo-Mora P, Luna R and Colin-Barenque L. Amyloid Beta: Multiple Mechanisms of Toxicity and Only Some Protective Effects? *Oxid Med Cell Longev*, **2014**. 2014: p. 795375.
20. Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR *et al*. The glial glutamate transporter, GLT 1, is oxidatively modified by 4 hydroxy 2 nonenal in the Alzheimer's disease brain: the role of A β 1-42. *J Neurochem*, **2001**. 78 (2): p. 413-416.

21. Decker H, Jurgensen S, Adrover MF, Brito-Moreira J, Bomfim TR, Klein WL *et al.* N Methyl d aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid β peptide oligomers. *J Neurochem*, **2010**. 115 (6): p. 1520-1529.
22. Martinez-Coria H, Green KN, Billings LM, Kitazawa M, Albrecht M, Rammes G *et al.* Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. *Am J Pathol*, **2010**. 176 (2): p. 870-880.
23. Alley GM, Bailey JA, Chen D, Ray B, Puli LK, Tanila H *et al.* Memantine lowers amyloid β peptide levels in neuronal cultures and in APP/PS1 transgenic mice. *J Neurosci Res*, **2010**. 88 (1): p. 143-154.
24. Tewes B, Frehland B, Schepmann D, Schmidtke K-U, Winckler T, Wunsch B. Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols. *Bioorg Med Chem*, **2010**. 18 (22): p. 8005-8015.
25. Thomas Mitchell, K, David M and Jeffrey Scott N. Lactam Compound. **2002**: p. WO2002040508 A2.
26. Solecka J, Guspiel A, Postek M, Ziemska J, Kawecki R, Leczycka K *et al.* New derivatives of 3,4-dihydroisoquinoline-3-carboxylic acid with free-radical scavenging, D-amino acid oxidase, acetylcholinesterase and butyrylcholinesterase inhibitory activity. *Molecules*, **2014**. 19 (10): p. 15866-90.
27. Nunez-Figueroa Y, Pardo-Andreu GL, Ramirez-Sanchez J, Delgado-Hernandez R, Ochoa-Rodriguez E, Verdecia-Reyes Y *et al.* Antioxidant effects of JM-20 on rat brain mitochondria and synaptosomes: mitoprotection against Ca(2)(+)-induced mitochondrial impairment. *Brain Res Bull*, **2014**. 109: p. 68-76.
28. Vellonen KS, Honkakoski P and Urtti A. Substrates and inhibitors of efflux proteins interfere with the MTT assay in cells and may lead to underestimation of drug toxicity. *Eur J Pharm Sci*, **2004**. 23 (2): p. 181-8.
29. Munoz-Ruiz, P., *et al.*, Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. *J Med Chem*, **2005**. 48 (23): p. 7223-33.
30. Kwon YE, Park JY, No KT, Shin JH, Lee SK, Eun JS *et al.* Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics. *Bioorg Med Chem*, **2007**. 15 (20): p. 6596-607.
31. Klunk WE, Jacob RF and Mason RP. Quantifying amyloid beta-peptide (Abeta) aggregation using the Congo red-Abeta (CR-abeta) spectrophotometric assay. *Anal Biochem*, **1999**. 266 (1): p. 66-76.
32. Kang, I.J., *et al.*, Butanol extract of *Ecklonia cava* prevents production and aggregation of beta-amyloid, and reduces beta-amyloid mediated neuronal death. *Food Chem Toxicol*, **2011**. 49 (9): p. 2252-9.
33. Sinha A, Jeon YE, Yin XF, Nam JS, You SG, Hong MS *et al.* Neuroprotective Role of Novel Triazine Derivatives by Activating Wnt/beta Catenin Signaling Pathway in Rodent Models of Alzheimer's Disease. *Mol Neurobiol*, **2015**. 52 (1): p. 638-52.
34. Yao M, Nguyen TV and Pike CJ. Beta-amyloid-induced neuronal apoptosis involves c-Jun N-terminal kinase-dependent downregulation of Bcl-w. *J Neurosci*, **2005**. 25 (5): p. 1149-58.

35. Muirhead KE, Borger E, Aitken L, Conway SJ, Gunn-Moore FJ. The consequences of mitochondrial amyloid beta-peptide in Alzheimer's disease. *Biochem J*, **2010**. 426 (3): p. 255-70.
36. Kaech S and Banker G. Culturing hippocampal neurons. *Nat Protoc*, **2006**. 1 (5): p. 2406-15.
37. Zha YY, Yang B, Tang ML, Guo QC, Chen JT, Wen LP *et al*. Concentration-dependent effects of fullerene on cultured hippocampal neuron viability. *Int J Nanomedicine*, **2012**. 7: p. 3099-109.
38. Liu D, Zhang H, Gu W, Liu Y, Zhang M. Neuroprotective effects of ginsenoside Rb1 on high glucose-induced neurotoxicity in primary cultured rat hippocampal neurons. *PLoS One*, **2013**. 8 (11): p. e79399.
39. Zhou S, Yang Y, Gu X, Ding F. Chitooligosaccharides protect cultured hippocampal neurons against glutamate-induced neurotoxicity. *Neurosci Lett*, **2008**. 444 (3): p. 270-4.
40. Brecht S, Gelderblom M, Srinivasan A, Mielke K, Dityateva G, Herdegen T. Caspase-3 activation and DNA fragmentation in primary hippocampal neurons following glutamate excitotoxicity. *Brain Res Mol Brain Res*, **2001**. 94 (1-2): p. 25-34.
41. Troy CM, Friedman JE and Friedman WJ. Mechanisms of p75-mediated death of hippocampal neurons. Role of caspases. *J Biol Chem*, **2002**. 277 (37): p. 34295-302.
42. Di L, Kerns EH, Fan K, McConnell OJ, Carter GT. High throughput artificial membrane permeability assay for blood-brain barrier. *Eur J Med Chem*, **2003**. 38 (3): p. 223-232.
43. Lu C, Guo Y, Yan J, Luo Z, Luo HB, Yan M *et al*. Design, synthesis, and evaluation of multitarget-directed resveratrol derivatives for the treatment of Alzheimer's disease. *J Med Chem*, **2013**. 56 (14): p. 5843-59.
44. Tucci P, Mhillaj E, Morgese MG, Colaianna M, Zotti M, Schiavone S *et al*. Memantine prevents memory consolidation failure induced by soluble beta amyloid in rats. *Front Behav Neurosci*, **2014**. 8: p. 332.
45. Colaianna M, Tucci P, Zotti M, Morgese MG, Schiavone S, Govoni S *et al*. Soluble beta amyloid(1-42): a critical player in producing behavioural and biochemical changes evoking depressive-related state? *Br J Pharmacol*, **2010**. 159 (8): p. 1704-15.
46. D'Hooge R and De Deyn PP. Applications of the Morris water maze in the study of learning and memory. *Brain Res Brain Res Rev*, **2001**. 36 (1): p. 60-90.
47. Yan JJ, Cho JY, Kim HS, Kim KL, Jung JS, Huh SO *et al*. Protection against beta-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. *Br J Pharmacol*, **2001**. 133 (1): p. 89-96.
48. Ramesh T, Kim SW, Sung JH, Hwang SY, Sohn SH, Yoo SK *et al*. Effect of fermented Panax ginseng extract (GINST) on oxidative stress and antioxidant activities in major organs of aged rats. *Exp Gerontol*, **2012**. 47 (1): p. 77-84.
49. Song MS, Rauw G, Baker GB, Kar S. Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation. *Eur J Neurosci*, **2008**. 28 (10): p. 1989-2002.
50. Reinhoud NJ, Brouwer HJ, van Heerwaarden LM, Korte-Bouws GA. Analysis of glutamate, GABA, noradrenaline, dopamine, serotonin, and metabolites using microbore UHPLC with electrochemical detection. *ACS Chem Neurosci*, **2013**. 4 (5): p. 888-94.
51. Cho J, Park C, Lee Y, Kim S, Bose S, Choi M *et al*. Neuroprotective and antioxidant effects of novel benzofuran-2-carboxamide derivatives. *Biomol Ther (Seoul)*, **2015**. 23 (3): p. 275-82.

52. Furukawa H, Singh SK, Mancusso R, Gouaux E. Subunit arrangement and function in NMDA receptors. *Nature*, **2005**. 438 (7065): p. 185-92.
53. Monaghan DT and Jane DE. Pharmacology of NMDA Receptors, in *Biology of the NMDA Receptor*, A.M. Van Dongen, Editor. **2009**.
54. Harkany T, Abraham I, Timmerman W, Laskay G, Toth B, Sasvari M *et al.* beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. *Eur J Neurosci*, **2000**. 12 (8): p. 2735-45.
55. Karran E, Mercken M and De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. *Nat Rev Drug Discov*, **2011**. 10 (9): p. 698-712.
56. Kelly BL and Ferreira A. Beta-amyloid disrupted synaptic vesicle endocytosis in cultured hippocampal neurons. *Neuroscience*, **2007**. 147 (1): p. 60-70.
57. Danysz W and Parsons CG. Alzheimer's disease, β amyloid, glutamate, NMDA receptors and memantine—searching for the connections. *Br J Pharmacol*, **2012**. 167 (2): p. 324-352.
58. Hengartner MO. The biochemistry of apoptosis. *Nature*, **2000**. 407 (6805): p. 770-776.
59. Butterfield DA. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. *Free Radic Res*, **2002**. 36 (12): p. 1307-13.
60. Behl C, Davis J, Cole GM, Schubert D. Vitamin E protects nerve cells from amyloid beta protein toxicity. *Biochem Biophys Res Commun*, **1992**. 186 (2): p. 944-50.
61. Alberdi E, Sanchez-Gomez MV, Cavaliere F, Perez-Samartin A, Zugaza JL, Trullas R *et al.* Amyloid beta oligomers induce Ca²⁺ dysregulation and neuronal death through activation of ionotropic glutamate receptors. *Cell Calcium*, **2010**. 47 (3): p. 264-72.
62. Bieschke J, Herbst M, Wiglenda T, Friedrich RP, Boeddrich A, Schiele F *et al.* Small-molecule conversion of toxic oligomers to nontoxic beta-sheet-rich amyloid fibrils. *Nat Chem Biol*, **2012**. 8 (1): p. 93-101.
63. Roth KA. Caspases, apoptosis, and Alzheimer disease: causation, correlation, and confusion. *J Neuropathol Exp Neurol*, **2001**. 60 (9): p. 829-38.
64. Greicius MD, Krasnow B, Boyett-Anderson JM, Eliez S, Schatzberg AF, Reiss AL *et al.* Regional analysis of hippocampal activation during memory encoding and retrieval: fMRI study. *Hippocampus*, **2003**. 13 (1): p. 164-74.
65. Hitti, FL and Siegelbaum SA. The hippocampal CA2 region is essential for social memory. *Nature*, **2014**. 508 (7494): p. 88-92.
66. Aguzzi A and O'Connor T. Protein aggregation diseases: pathogenicity and therapeutic perspectives. *Nat Rev Drug Discov*, **2010**. 9 (3): p. 237-48.
67. Blurton-Jones M and Laferla FM. Pathways by which A β facilitates tau pathology. *Curr Alzheimer Res*, **2006**. 3 (5): p. 437-48.
68. Dobarro M, Gerenu G and Ramirez MJ. Propranolol reduces cognitive deficits, amyloid and tau pathology in Alzheimer's transgenic mice. *Int J Neuropsychopharmacol*, **2013**. 16 (10): p. 2245-57.
69. Brion JP, Anderton BH, Authelet M, Dayanandan R, Leroy K, Lovestone S *et al.* Neurofibrillary tangles and tau phosphorylation. *Biochem Soc Symp*, **2001**. 67: p. 81-8.
70. Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribe E, Dalfo E, Avila J. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. *Curr Alzheimer Res*, **2005**. 2 (1): p. 3-18.

71. Wang JZ, Grundke-Iqbal I and Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. *Eur J Neurosci*, **2007**. 25 (1): p. 59-68.
72. Watkins JC. Pharmacology of excitatory amino acid transmitters. *Adv Biochem Psychopharmacol*, **1981**. 29: p. 205-12.
73. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. *Pharmacol Rev*, **1999**. 51 (1): p. 7-61.
74. Flores-Soto ME, Chaparro-Huerta V, Escoto-Delgadillo M, Vazquez-Valls E, Gonzalez-Castaneda RE, Beas-Zarate C. Structure and function of NMDA-type glutamate receptor subunits. *Neurologia*, **2012**. 27 (5): p. 301-10.
75. Dong, XX, Wang Y and Qin ZH. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. *Acta Pharmacol Sin*, **2009**. 30 (4): p. 379-87.
76. Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. *Pharmacol Ther*, **1999**. 81 (3): p. 163-221.
77. Petroff OA. GABA and glutamate in the human brain. *Neuroscientist*, **2002**. 8 (6): p. 562-73.
78. Kohr G. NMDA receptor function: subunit composition versus spatial distribution. *Cell Tissue Res*, **2006**. 326 (2): p. 439-446.
79. Hardingham GE. Coupling of the NMDA receptor to neuroprotective and neurodestructive events. *Biochem Soc Trans*, **2009**. 37 (6): p. 1147-60.
80. Gonzalez J, Jurado-Coronel JC, Avila MF, Sabogal A, Capani F, Barreto GE. NMDARs in neurological diseases: a potential therapeutic target. *Int J Neurosci*, **2015**. 125 (5): p. 315-27.
81. Barger SW and Basile AS. Activation of microglia by secreted amyloid precursor protein evokes release of glutamate by cystine exchange and attenuates synaptic function. *J Neurochem*, **2001**. 76 (3): p. 846-54.
82. Wenk GL, Baker LM, Hauss-Wegrzyniak B, Danysz W, Stoehr JD. Novel glycineB antagonists show neuroprotective activity in vivo. *Amino Acids*, **1998**. 14 (1-3): p. 223-6.
83. Nagata R, Tanno N, Kodo T, Ae N, Yamaguchi H, Nishimura T *et al*. Tricyclic Quinoxalinediones: 5,6-Dihydro-1H-pyrrolo[1,2,3-de]quinoxaline-2,3-diones and 6,7-Dihydro-1H,5H-pyrido[1,2,3-de]quinoxaline-2,3-diones as Potent Antagonists for the Glycine Binding Site of the NMDA Receptor. *J Med Chem*, **1994**. 37 (23): p. 3956-3968.
84. Chapdelaine MJ and McLaren CD. Therapeutic Benzazarine Compounds. U.S. Patent **1993**. 5 (254,683).
85. Kemp JA and Leeson PD. The glycine site of the NMDA receptor--five years on. *Trends Pharmacol Sci*, **1993**. 14 (1): p. 20-5.
86. Kulagowski JJ, Baker R, Curtis NR, Leeson PD, Mawer IM, Moseley AM *et al*. 3'-(Arylmethyl)- and 3'-(aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: orally active antagonists of the glycine site on the NMDA receptor. *J Med Chem*, **1994**. 37 (10): p. 1402-5.
87. Keana JF, Kher SM, Cai SX, Dinsmore CM, Glenn AG, Guastella J *et al*. Synthesis and structure-activity relationships of substituted 1,4-dihydroquinoxaline-2,3-diones: antagonists of N-methyl-D-aspartate (NMDA) receptor glycine sites and non-NMDA glutamate receptors. *J Med Chem*, **1995**. 38 (22): p. 4367-79.
88. Guzikowski AP, Cai SX, Espitia SA, Hawkinson JE, Huettner JE, Nogales DF *et al*. Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. *J Med Chem*, **1996**. 39 (23): p. 4643-53.

89. Swartz KJ, Koroshetz WJ, Rees AH, Huettner JE. Competitive antagonism of glutamate receptor channels by substituted benzazepines in cultured cortical neurons. *Mol Pharmacol*, **1992**. 41 (6): p. 1130-41.
90. Miguel-Hidalgo, J.J., *et al.*, Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). *Brain Res*, **2002**. 958 (1): p. 210-21.
91. Guo, Q., *et al.*, Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. *Nat Med*, **1999**. 5 (1): p. 101-6.
92. Moechars D, Alvarez XA, Cacabelos R, Quack G. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. *J Biol Chem*, **1999**. 274 (10): p. 6483-92.
93. Carrillo-Mora P, Luna R and Colin-Barenque L. Amyloid beta: multiple mechanisms of toxicity and only some protective effects? *Oxid Med Cell Longev*, **2014**. 2014: p. 795375.
94. Nicholls DG. Mitochondrial dysfunction and glutamate excitotoxicity studied in primary neuronal cultures. *Curr Mol Med*, **2004**. 4 (2): p. 149-77.
95. Girouard H, Wang G, Gallo EF, Anrather J, Zhou P, Pickel VM *et al.* NMDA receptor activation increases free radical production through nitric oxide and NOX2. *J Neurosci*, **2009**. 29 (8): p. 2545-52.
96. Lee DH, Park T and Kim HW. Induction of apoptosis by disturbing mitochondrial-membrane potential and cleaving PARP in Jurkat T cells through treatment with acetoxycirpenol mycotoxins. *Biol Pharm Bull*, **2006**. 29 (4): p. 648-54.
97. Oliver FJ, Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G, Murcia JM. Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. *J Biol Chem*, **1998**. 273 (50): p. 33533-9.
98. Chaitanya GV, Steven AJ and Babu PP. PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. *Cell Commun Signal*, **2010**. 8 (1): p. 31.
99. Strosznajder JB, Jesko H and Strosznajder RP. Effect of amyloid beta peptide on poly(ADP-ribose) polymerase activity in adult and aged rat hippocampus. *Acta Biochim Pol*, **2000**. 47 (3): p. 847-54.
100. Adamczyk A, Jesko H and Strosznajder RP. Alzheimer's disease related peptides affected cholinergic receptor mediated poly(ADP-ribose) polymerase activity in the hippocampus. *Folia Neuropathol*, **2005**. 43 (3): p. 139-42.
101. Sairanen T, Szepesi R, Karjalainen-Lindsberg ML, Saksi J, Paetau A, Lindsberg PJ. Neuronal caspase-3 and PARP-1 correlate differentially with apoptosis and necrosis in ischemic human stroke. *Acta Neuropathol*, **2009**. 118 (4): p. 541-52.
102. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. *Nature*, **2003**. 423 (6938): p. 435-9.
103. Ma, QL, Lim GP, Harris-White ME, Yang F, Ambegaokar SS, Ubeda OJ *et al.* Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. *J Neurosci Res*, **2006**. 83 (3): p. 374-84.

6. REFERENCES

1. Koob GF and Volkow ND. Neurocircuitry of addiction. *Neuropsychopharmacol*, **2010**. 35 (1): p. 217-238.
2. Beaulieu JM and Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. *Pharmacol Rev*, **2011**. 63 (1): p. 182-217.
3. Iversen SD and Iversen LL. Dopamine: 50 years in perspective. *Trends Neurosci*, **2007**. 30 (5): p. 188-193.
4. Keibalian JW and Calne DB. Multiple receptors for dopamine. *Nature*, **1979**. 277 (5692): p. 93-96.
5. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. *Physiol Rev*, **1998**. 78 (1): p. 189-225.
6. Malenka R, Nestler E and Hyman S. Chapter 6: Widely Projecting Systems: Monoamines, Acetylcholine, and Orexin. Sydor A, Brown RY. *Mol Neuropharmacol*, New York: McGraw-Hill Medical, **2009**: p. 147-148.
7. Butterfield DA. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. *Free Radic Res*, **2002**. 36 (12): p. 1307-1313.
8. Zawilska JB. Dopamine receptors--structure, characterization and function. *Postepy Hig Med Dosw*, **2003**. 57 (3): p. 293-322.
9. Rankin ML, Hazelwood LA, Free RB, Namkung Y, Rex EB, Roof RA *et al*. 3.1 Molecular Pharmacology of the Dopamine Receptors. *Dopamine Handbook*, **2010**. 63.
10. Monsma FJ, McVittie LD, Gerfen CR, Mahan LC, Sibley DR. Multiple D2 dopamine receptors produced by alternative RNA splicing. *Nature*, **1989**. 342 (6252): p. 926-929.
11. Rondou P, Haegeman G and Van Craenenbroeck K. The dopamine D4 receptor: biochemical and signalling properties. *Cell Mol Life Sci*, **2010**. 67 (12): p. 1971-1986.
12. Sokoloff P, Andrieux M, Besançon R, Pilon C, Martres MP, Giros B, Schwartz JC. The Dopamine D3 Receptor: A Therapeutic Target for the Treatment of Neuropsychiatric Disorders. *CNS Neurol Dis*, **2006**. 5 (1): p. 25-43.
13. Sibley DR. New insights into dopaminergic receptor function using antisense and genetically altered animals. *Annu Rev Pharmacol Toxicol*, **1999**. 39: p. 313-341.
14. Beitz JM. Parkinson's disease: a review. *Front Biosci*, **2014**. 6: p. 65-74.
15. Galvan A and Wichmann T. Pathophysiology of parkinsonism. *Clin Neurophysiol*, **2008**. 119 (7): p. 1459-1474.
16. Hwang O. Role of oxidative stress in Parkinson's disease. *Exp Neurobiol*, **2013**. 22 (1): p. 11-17.
17. Hattoria N, Wanga M, Taka H, Fujimura T, Yoritaka A, Kubo S, Mochizuki H. Toxic effects of dopamine metabolism in Parkinson's disease. *Parkinsonism Relat Disord*, **2009**. 15 Suppl 1: p. S35-S38.
18. Rommelfanger KS and Wichmann T. Extrastriatal dopaminergic circuits of the Basal Ganglia. *Front Neuroanat*, **2010**. 4: p. 139.

19. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A *et al.* Levodopa and the progression of Parkinson's disease. *N Engl J Med*, **2004**. 351 (24): p. 2498-2508.
20. Giardina WJ and Williams M. Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. *CNS Drug Rev*, **2001**. 7 (3): p. 305-316.
21. Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD. Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate. *Psychopharmacol*, **1995**. 117 (4): p. 403-412.
22. Lei S, Orensanz LM, Mulvany MJ, Simonsen U. Mechanisms involved in the vasorelaxant effect of (-)-stepholidine in rat mesenteric small arteries. *Eur J Pharmacol*, **1999**. 365 (2-3): p. 193-204.
23. Guo S, Bezard E and Zhao B. Protective effect of green tea polyphenols on the SH-SY5Y cells against 6-OHDA induced apoptosis through ROS-NO pathway. *Free Radic Biol Med*, **2005**. 39 (5): p. 682-695.
24. Mohamed T, Zhao X, Habib LK, Yang J, Rao PP. Design, synthesis and structure-activity relationship (SAR) studies of 2,4-disubstituted pyrimidine derivatives: dual activity as cholinesterase and Abeta-aggregation inhibitors. *Bioorg Med Chem*, **2011**. 19 (7): p. 2269-2281.
25. Kakko I, Toimela T and Tähti H. The toxicity of pyrethroid compounds in neural cell cultures studied with total ATP, mitochondrial enzyme activity and microscopic photographing. *Env Tox Pharmacol*, **2004**. 15 (2): p. 95-102.
26. Chaturvedi R, Shukla S, Seth K, Chauhan S, Sinha C, Shukla Y *et al.* Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease. *Neurobiol Dis*, **2006**. 22 (2): p. 421-434.
27. Gulwadi AG, Korpinen CD, Mailman RB, Nichols DE, Sit S-Y, Taber MT. Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease. *J Pharmacol Exp Ther*, **2001**. 296 (2): p. 338-344.
28. Moron MS, Depierre JW and Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. *Biochim Biophys Acta*, **1979**. 582(1): p. 67-78.
29. Uchiyama M and Mihara M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. *Anal Biochem*, **1978**. 86 (1): p. 271-278.
30. Misra HP and Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. *J Biol Chem*, **1972**. 247 (10): p. 3170-3175.
31. Sinha AK. Colorimetric assay of catalase. *Anal Biochem*, **1972**. 47 (2): p. 389-394.
32. Sharma N and Nehru B. Beneficial Effect of Vitamin E in Rotenone Induced Model of PD: Behavioural, Neurochemical and Biochemical Study. *Exp Neurobiol*, **2013**. 22 (3): p. 214-223.

33. Jin G, He XR and Chen LP. The protective effect of ginkgo bilboa leaves injection on the brain dopamine in the rat model of cerebral ischemia/reperfusion injury. *Afr Health Sci*, **2014**. 14 (3): p. 725-728.
34. Kim C, Speisky MB and Kharouba SN. Rapid and sensitive method for measuring norepinephrine, dopamine, 5-hydroxytryptamine and their major metabolites in rat brain by high-performance liquid chromatography. Differential effect of probenecid, haloperidol and yohimbine on the concentrations of biogenic amines and metabolites in various regions of rat brain. *J Chromatogr*, **1987**. 386: p. 25-35.
35. Pycock C. Turning behaviour in animals. *Neuroscience*, **1980**. 5 (3): p. 461-514.
36. Ungerstedt U. Postsynaptic supersensitivity after 6 hydroxy dopamine induced degeneration of the nigro striatal dopamine system. *Acta Physiol Scand*, **1971**. 82 (S367): p. 69-93.
37. Creese I, Burt DR and Snyder SH. Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. *Science*, **1977**. 197 (4303): p. 596-598.
38. Sedaghat R, Roghani M and Khalili M. Neuroprotective effect of thymoquinone, the nigella sativa bioactive compound, in 6-hydroxydopamine-induced hemi-parkinsonian rat model. *Iran J Pharm Res*, **2014**. 13 (1): p. 227-234.
39. Chan HH, Kumar S and Zhuo L. Neuroprotective and behavioural assessments of an imidazolium compound (DBZIM) in a rat model of Parkinson's disease induced by 6-OHDA. *Eur J Pharmacol*, **2013**. 715 (1): p. 405-413.
40. Cortes R, Gueye B, Pazos A, Probst A, Palacios J. Dopamine receptors in human brain: autoradiographic distribution of D 1 sites. *Neuroscience*, **1989**. 28 (2): p. 263-273.
41. Richfield EK, Young AB and Penney JB. Comparative distributions of dopamine D 1 and D 2 receptors in the cerebral cortex of rats, cats, and monkeys. *J Compar Neurol*, **1989**. 286 (4): p. 409-426.
42. Hurley MJ, Mash DC and Jenner P. Dopamine D 1 receptor expression in human basal ganglia and changes in Parkinson's disease. *Mol Brain Res*, **2001**. 87 (2): p. 271-279.
43. Smith Y and Kieval JZ. Anatomy of the dopamine system in the basal ganglia. *Trends Neurosci*, **2000**. 23: p. S28-S33.
44. Waszczak BL, Martin LP, Finlay HE, Zahr N, Stellar JR. Effects of individual and concurrent stimulation of striatal D1 and D2 dopamine receptors on electrophysiological and behavioral output from rat basal ganglia. *J Pharmacol Exp Ther*, **2002**. 300 (3): p. 850-861.
45. Bedard PJ and Boucher R. Effect of D 1 receptor stimulation in normal and MPTP monkeys. *Neurosci lett*, **1989**. 104 (1): p. 223-228.
46. Gagnon C, Bedard PJ and Di Paolo T. Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists. *Eur J Pharmacol*, **1990**. 178 (1): p. 115-120.
47. DeNinno MP, Schoenleber R, Perner RJ, Lijewski L, Asin KE, Britton DR *et al*. Synthesis and dopaminergic activity of 3-substituted 1-(aminomethyl)-3, 4-dihydro-5, 6-dihydroxy-

- 1H-2-benzopyrans: characterization of an auxiliary binding region in the D₁ receptor. *J Med Chem*, **1991**. 34 (8): p. 2561-2569.
48. DeNinno MP, Schoenleber R, MacKenzie R, Britton DR, Asin KE, Briggs C *et al*. A68930: a potent agonist selective for the dopamine D₁ receptor. *Eur J Pharmacol*, **1991**. 199 (2): p. 209-219.
49. Taylor JR, Lawrence MS, Redmond DE, Elsworth JD, Roth RH, Nichols DE *et al*. Dihydroxidine, a full dopamine D₁ agonist, reduces MPTP-induced parkinsonism in monkeys. *Eur J Pharmacol*, **1991**. 199 (3): p. 389-391.
50. Calabresi P, Picconi B, Tozzi A, Ghiglieri V, Di Filippo M. Direct and indirect pathways of basal ganglia: a critical reappraisal. *Nature Neurosci*, **2014**. 17 (8): p. 1022-1030.
51. Meloni EG and Davis M. Enhancement of the acoustic startle response by dopamine agonists after 6-hydroxydopamine lesions of the substantia nigra pars compacta: corresponding changes in c-Fos expression in the caudate-putamen. *Brain Res*, **2000**. 879 (1): p. 93-104.
52. Keibarian JW and Saavedra JM. Dopamine-sensitive adenylate cyclase occurs in a region of substantia nigra containing dopaminergic dendrites. *Science*, **1976**. 193 (4254): p. 683-685.
53. Trugman JM and Wooten GF. The effects of DOPA on regional cerebral glucose utilization in rats with unilateral lesions of the substantia nigra. *Brain Res*, **1986**. 379 (2): p. 264-274.
54. Trugman JM and Wooten GF. Selective D₁ and D₂ dopamine agonists differentially alter basal ganglia glucose utilization in rats with unilateral 6-hydroxydopamine substantia nigra lesions. *J Neurosci*, **1987**. 7 (9): p. 2927-2935.
55. Trugman JM, Arnold WS, Touchet N, Wooten GF. D₁ dopamine agonist effects assessed in vivo with [¹⁴C]-2-deoxyglucose autoradiography. *J Pharmacol Exp Ther*, **1989**. 250 (3): p. 1156-1160.
56. Trugman JM, James CL and Wooten GF. D₁/D₂ dopamine receptor stimulation by L-DOPA. *Brain*, **1991**. 114 (3): p. 1429-1440.
57. Heikkila R, Sonsalla P and Duvoisin R. Biochemical models of Parkinson's disease. *Drugs Tools Neurotrans Res*, **1989**: p. 351-384.
58. Berger K, Przedborski S and Cadet JL. Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats. *Brain Res Bull*, **1991**. 26 (2): p. 301-307.
59. Cadet JL, Last R, Kostic V, Przedborski S, Jackson-Lewis V. Long-term behavioral and biochemical effects of 6-hydroxydopamine injections in rat caudate-putamen. *Brain Res Bull*, **1991**. 26 (5): p. 707-713.
60. Bredesen DE. Neural apoptosis. *Annals Neurol*, **1995**. 38 (6): p. 839-851.
61. Costa, CA, Paitel E, Vincent B, Checler F. α -Synuclein Lowers p53-dependent Apoptotic Response of Neuronal Cells Abolishment by 6-Hydroxydopamine and Implication for Parkinson's Disease. *J Biol Chem*, **2002**. 277 (52): p. 50980-50984.

62. Jenner P. Oxidative stress in Parkinson's disease. *Annals Neurol*, **2003**. 53 (S3): p. S26-S38.
63. Bharath S, Hsu M, Kaur D, Rajagopalan S, Andersen JK. Glutathione, iron and Parkinson's disease. *Biochem Pharmacol*, **2002**. 64 (5): p. 1037-1048.
64. Kerksick C and Willoughby D. The antioxidant role of glutathione and N-acetyl-cysteine supplements and exercise-induced oxidative stress. *J Int Soc Sports Nut*, **2005**. 2 (2): p. 1.
65. Wang XF and Cynader MS. Astrocytes provide cysteine to neurons by releasing glutathione. *J Neurochem*, **2000**. 74 (4): p. 1434-1442.
66. Micheau O, Thome M, Schneider P, Holler N, Tschopp J, Nicholson DW *et al*. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. *J Biol Chem*, **2002**. 277 (47): p. 45162-45171.
67. Wajant H. The Fas signaling pathway: more than a paradigm. *Science*, **2002**. 296 (5573): p. 1635-1636.
68. Hengartner MO. The biochemistry of apoptosis. *Nature*, **2000**. 407 (6805): p. 770-776.
69. Chen Q, Chai Y, Mazumder S, Jiang C, Macklis R, Chisolm G *et al*. The late increase in intracellular free radical oxygen species during apoptosis is associated with cytochrome c release, caspase activation, and mitochondrial dysfunction. *Cell Death Differ*, **2003**. 10 (3): p. 323-334.
70. Jiang X and Wang X. Cytochrome C-mediated apoptosis. *Annu Rev Biochem*, **2004**. 73 (1): p. 87-106.
71. Twiddy D, Brown DG, Adrain C, Jukes R, Martin SJ, Cohen GM *et al*. Pro-apoptotic proteins released from the mitochondria regulate the protein composition and caspase-processing activity of the native Apaf-1/caspase-9 apoptosome complex. *J Biol Chem*, **2004**. 279 (19): p. 19665-19682.
72. Lauber K, Appel HA, Schlosser SF, Gregor M, Schulze-Osthoff K, Wesselborg S. The adapter protein apoptotic protease-activating factor-1 (Apaf-1) is proteolytically processed during apoptosis. *J Biol Chem*, **2001**. 276 (32): p. 29772-29781.
73. Tanaka K and Ogawa N. Dopamine agonist cabergoline inhibits levodopa-induced caspase activation in 6-OHDA-lesioned mice. *Neurosci Res*, **2005**. 51 (1): p. 9-13.

6. REFERENCES

1. Beaulieu JM and RR Gainetdinov. The physiology, signaling, and pharmacology of dopamine receptors. *Pharmacol Rev*, **2011**. 63 (1): p. 182-217.
2. WHO, Schizophrenia Fact sheet N°397. September 2015: p. Retrived 30 March **2016**.
3. Schultz SH, North SW and Shields CG. Schizophrenia: a review. *Am Fam Physician*, **2007**. 75 (12): p. 1821-9.
4. Van Os J and Kapur S. Schizophrenia. *Lancet*, **2009**. 374 (9690): p. 635-45.
5. Geddes J, Freemantle N, Harrison P and Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. *BMJ*, **2000**. 321 (7273): p. 1371-1376.
6. Millan MJ, Seguin L, Gobert A, Cussac D and Brocco M. The role of dopamine D₃ compared with D₂ receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. *Psychopharmacol*, **2004**. 174 (3): p. 341-357.
7. Sokoloff P, Giros B, Martres MP, Andrieux M, Besancon R, Pilon C *et al*. Localization and function of the D₃ dopamine receptor. *Arzneimittelforschung*, **1992**. 42 (2A): p. 224-30.
8. Micheli F, Bonanomi G, Braggio S, Capelli AM, Celestini P, Damiani F *et al*. New fused benzazepine as selective D₃ receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems. *Bioorg Med Chem Lett*, **2008**. 18 (3): p. 901-7.
9. Micheli F, Bonanomi G, Braggio S, Capelli AM, Damiani F, Di Fabio R *et al*. New fused benzazepine as selective D₃ receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems. *Bioorg Med Chem Lett*, **2008**. 18 (3): p. 908-12.
10. Micheli F. Recent Advances in the Development of Dopamine D₃ Receptor Antagonists: a Medicinal Chemistry Perspective. *ChemMedChem*, **2011**. 6 (7): p. 1152-1162.
11. Gurevich EV, Bordelon Y, Shapiro RM, Arnold SE, Gur RE and Joyce JN. Mesolimbic dopamine D₃ receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. *Arch Gen Psychiatry*, **1997**. 54 (3): p. 225-32.
12. Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC and Sokoloff P. BDNF controls dopamine D₃ receptor expression and triggers behavioural sensitization. *Nature*, **2001**. 411 (6833): p. 86-89.
13. Jonsson EG, Flyckt L, Burgert E, Crocq MA, Forslund K, Mattila-Evenden M *et al*. Dopamine D₃ receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis. *Psychiat Genet*, **2003**. 13 (1): p. 1-12.
14. Silverdale MA, Nicholson SL, Ravenscroft P, Crossman AR, Millan MJ and Brotchie JM. Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate. *Exp Neurol*, **2004**. 188 (1): p. 128-38.
15. Park WK, Jeong D, Yun CW, Lee S, Cho H, Kim GD *et al*. Pharmacological actions of a novel and selective dopamine D₃ receptor antagonist, KCH-1110. *Pharmacol Res*, **2003**. 48 (6): p. 615-22.
16. Kongsamut S, Hendrix J, Bordeau K, Strupczewski J, Harris B, Kenney M *et al*. Ave5997, a dopamine D₃ antagonist for the treatment of schizophrenia. *Schizophrenia Res*, **2003**. 60 (1, Supplement): p. 312.

17. Vonderfecht SL, Stone ML, Eversole RR, Yancey MF, Schuette MR, Duncan BA *et al.* Myopathy related to administration of a cationic amphiphilic drug and the use of multidose drug distribution analysis to predict its occurrence. *Toxicol Pathol*, **2004**. 32 (3): p. 318-25.
18. Lahti AC, Weiler M, Carlsson A and Tamminga CA. Effects of the D₃ and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia. *J Neural Transm*, **1998**. 105 (6-7): p. 719-34.
19. Machado MS, Rosa RM, Dantas AS, Reolon GK, Appelt HR, Braga AL *et al.* An organic selenium compound attenuates apomorphine-induced stereotypy in mice. *Neuroscience Lett*, **2006**. 410 (3): p. 198-202.
20. Zuideveld KP, Maas HJ, Treijtel N, Hulshof J, Graaf PH, Peletier LA *et al.* A set-point model with oscillatory behavior predicts the time course of 8-OH-DPAT-induced hypothermia. *Am J Physiol Regul Integr Comp Physiol*, **2001**. 281 (6): p. R2059-R2071.
21. Marchese G, Casti P, Ruiu S, Saba P, Sanna A, Casu G and Pani L. Haloperidol, but not clozapine, produces dramatic catalepsy in delta9-THC-treated rats: possible clinical implications. *Br J Pharmacol*, **2003**. 140 (3): p. 520-6.
22. Singh S, Ahmed R, Sagar RK and Krishana B. Neuroprotection of the nigrostriatal dopaminergic neurons by melatonin in hemiparkinsonium rat. *Ind J Med Res*, **2006**. 124 (4): p. 419-26.
23. Sharma N and Nehru B. Beneficial Effect of Vitamin E in Rotenone Induced Model of PD: Behavioural, Neurochemical and Biochemical Study. *Exp Neurobiol*, **2013**. 22 (3): p. 214-223.
24. Jin G, He XR and Chen LP. The protective effect of ginko bilboa leaves injection on the brain dopamine in the rat model of cerebral ischemia/reperfusion injury. *Afr Health Sci*, **2014**. 14 (3): p. 725-8.
25. Kim C, Speisky MB and Kharouba SN. Rapid and sensitive method for measuring norepinephrine, dopamine, 5-hydroxytryptamine and their major metabolites in rat brain by high-performance liquid chromatography. Differential effect of probenecid, haloperidol and yohimbine on the concentrations of biogenic amines and metabolites in various regions of rat brain. *J Chromatogr*, **1987**. 386: p. 25-35.
26. Gyertyan I and Saghy K. Effects of dopamine D₃ receptor antagonists on spontaneous and agonist-reduced motor activity in NMRI mice and Wistar rats: comparative study with nafadotride, U 99194A and SB 277011. *Behav Pharmacol*, **2004**. 15 (4): p. 253-62.
27. Seeman P. Dopamine D₂ receptors as treatment targets in schizophrenia. *Clin Schizophr Relat Psychoses*, **2010**. 4 (1): p. 56-73.
28. Copolov DL, Link C and Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia. *Psychol Med*, **2000**. 30 (01): p. 95-105.
29. Missale C, Nash SR, Robinson SW, Jaber M and Caron MG. Dopamine receptors: from structure to function. *Physiol Rev*, **1998**. 78 (1): p. 189-225.
30. Macdonald GJ, Branch CL, Hadley MS, Johnson CN, Nash DJ, Smith AB *et al.* Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))-phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D₃ receptor antagonist. *J Med Chem*, **2003**. 46 (23): p. 4952-64.

31. Vasse M and Protais P. Potentiation of apomorphine-induced stereotyped behaviour by acute treatment with dopamine depleting agents: a potential role for an increased stimulation of D1 dopamine receptors. *Neuropharmacol*, **1989**. 28 (9): p. 931-9.
32. O'Neill MF and Shaw G. Comparison of dopamine receptor antagonists on hyperlocomotion induced by cocaine, amphetamine, MK-801 and the dopamine D1 agonist C-APB in mice. *Psychopharmacol*, **1999**. 145 (3): p. 237-250.
33. Abekawa T, Honda M, Ito K and Koyama T. Effects of NRA0045, a novel potent antagonist at dopamine D4, 5-HT2A, and alpha1 adrenaline receptors, and NRA0160, a selective D4 receptor antagonist, on phencyclidine-induced behavior and glutamate release in rats. *Psychopharmacol*, **2003**. 169 (3-4): p. 247-56.
34. Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY *et al*. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. *J Pharmacol Exp Ther*, **2000**. 294 (3): p. 1154-65.
35. Haadsma Svensson SR and Svensson KA. PNU 99194A: A Preferential Dopamine D3 Receptor Antagonist. *CNS Drug Rev*, **1998**. 4 (1): p. 42-53.
36. Manzanedo C, Aguilar MA and Minarro J. The effects of dopamine D2 and D3 antagonists on spontaneous motor activity and morphine-induced hyperactivity in male mice. *Psychopharmacol*, **1999**. 143 (1): p. 82-8.
37. Corbin AE, Pugsley TA, Akunne HC, Whetzel SZ, Zoski KT, Georgic LM *et al*. Pharmacological characterization of PD 152255, a novel dimeric benzimidazole dopamine D3 antagonist. *Pharmacol Biochem Behav*, **1998**. 59 (2): p. 487-93.
38. Fink-Jensen A, Nielsen EB, Hansen L and Scheideler MA. Behavioral and neurochemical effects of the preferential dopamine D3 receptor agonist cis-8-OH-PBZI. *Eur J Pharmacol*, **1998**. 342 (2-3): p. 153-61.
39. Salmi P, Karlsson T and Ahlenius S. Antagonism by SCH 23390 of clozapine-induced hypothermia in the rat. *Eur J Pharmacol*, **1994**. 253 (1-2): p. 67-73.
40. Corripio I, Ferreira A, Portella MJ, Perez V, Escarti MJ, Del Valle Camacho M *et al*. The role of striatal dopamine D2 receptors in the occurrence of extrapyramidal side effects: iodine-123-iodobenzamide single photon emission computed tomography study. *Psychiatry Res*, **2012**. 201 (1): p. 73-7.